HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) is holding a webinar today at 4:15 p.m. ET.
During this event, hosted by RedChip Companies, Nexalin’s CEO Mark White will discuss the company’s latest clinical data. This data supports their innovative deep brain stimulation device, which uses non-invasive frequency-based technology. Nexalin is making strides with their new Gen-3 HALO™ Clarity & Virtual Clinic model. Their devices have been beneficial in treating common yet challenging issues like insomnia, PTSD, and traumatic brain injuries, which impact millions. The mental health treatment market is set to grow significantly, reaching an estimated $537 billion by 2030. Following the presentation, attendees can participate in a live Q&A with White.
To join the webinar, visit: https://redchip.zoom.us/webinar/register/WN_5oARuMZLTneaMtsRpZshQQ.
Participants can send questions ahead of time to NXL@redchip.com or ask them live during the event.
About Nexalin Technology, Inc.
Nexalin is focused on developing neurostimulation products aimed at addressing the global mental health crisis. Their offerings are designed to be non-invasive and safe for the body. Utilizing advanced bioelectronic technology, Nexalin aims to treat mental health conditions effectively. The company believes its specialized devices can reach deep into the brain areas linked to these disorders, providing relief without side effects. Their Gen-2 device has already gained approval in China, Brazil, and Oman. For more details, visit: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This release includes “forward-looking statements.” These are predictions about future events and the company’s financial performance. They may refer to expectations or plans and can involve risks that might cause actual results to differ. Many factors, including those detailed in the Risk Factors section of the Company’s Report on Form 10-K, could influence these outcomes. These statements are made today and may not be updated, except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NXL@redchip.com
Source link
Nasdaq:NXL, Nexalin Technology, Inc., Nexalin Technology, Inc.
